Short Interest in PainReform Ltd. (NASDAQ:PRFX) Declines By 36.6%

PainReform Ltd. (NASDAQ:PRFXGet Rating) saw a significant decrease in short interest in March. As of March 31st, there was short interest totalling 48,000 shares, a decrease of 36.6% from the March 15th total of 75,700 shares. Based on an average daily trading volume, of 122,400 shares, the short-interest ratio is currently 0.4 days. Currently, 0.9% of the shares of the stock are sold short.

Shares of NASDAQ PRFX traded down $0.02 during trading on Friday, hitting $1.20. The company had a trading volume of 26,971 shares, compared to its average volume of 203,330. PainReform has a 52 week low of $0.82 and a 52 week high of $7.84. The business’s 50-day moving average is $1.13 and its 200 day moving average is $1.63.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new position in shares of PainReform in the second quarter valued at $49,000. Geode Capital Management LLC bought a new position in shares of PainReform in the third quarter valued at $62,000. Susquehanna International Group LLP bought a new position in shares of PainReform in the fourth quarter valued at $34,000. Finally, Citadel Advisors LLC increased its holdings in shares of PainReform by 22.0% in the second quarter. Citadel Advisors LLC now owns 33,735 shares of the company’s stock valued at $95,000 after buying an additional 6,073 shares in the last quarter. 15.21% of the stock is currently owned by institutional investors.

About PainReform (Get Rating)

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

See Also

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with's FREE daily email newsletter.